Opus Genetics

Opus Genetics EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Opus Genetics (IRD) as of Oct 17, 2026 is -95.78 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -168.40 % — a change of -43.12% (higher).

EBIT/Assets

-95.78 %

YoY

-43.12%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Opus Genetics is 2025 -95.78 % . Operating Income to Assets Ratio (EBIT/Assets) of Opus Genetics was 2024 -168.40 % . It decreases by -43.12% higher compared to the previous year.

The Opus Genetics EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-128.05 USD
Jan 1, 2019
-235.03 USD
Jan 1, 2020
-100.51 USD
Jan 1, 2021
-217.40 USD
Jan 1, 2022
37.20 USD
Jan 1, 2023
-18.49 USD
Jan 1, 2024
-168.40 USD
Jan 1, 2025
-95.78 USD
The Opus Genetics EBIT/Assets history
YEAREBIT/AssetsYoY
-95.78 %-43.12%
-168.40 %+810.83%
-18.49 %-149.70%
37.20 %-117.11%
-217.40 %+116.29%
-100.51 %-57.23%
-235.03 %+83.54%
-128.05 %+108.80%
-61.33 %-21.37%
-77.99 %+5.97%
-73.60 %+85.97%
-39.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Opus Genetics Stock analysis

What does Opus Genetics do? Ocuphire Pharma, Inc. is a health care company based in Farmington Hills, Michigan, specializing in the research and development of ophthalmic biopharmaceuticals. Listed on the market on 30 November 2004, the firm focuses on therapies for refractive and retinal eye disorders. Its pipeline features Nyxol Eye Drops, a once-daily formulation of phentolamine mesylate aimed at reducing pupil diameter and improving visual acuity for conditions such as presbyopia and night vision disturbances. Additionally, the company develops APX3330, an oral tablet targeting retinal and choroidal diseases, alongside in-licensed second-generation candidates APX2009 and APX2014. The organization employs a small team dedicated to advancing these innovative treatments. Opus Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opus Genetics stock

Operating Income to Assets Ratio (EBIT/Assets) of Opus Genetics is -95.78 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Opus Genetics changed from -168.40 % to -95.78 %, representing a -43.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Opus Genetics since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Opus Genetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Opus Genetics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Opus Genetics